Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.

Columnist Desiree Lama describes her journey with MS-related bladder problems that were brought under control but are now ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Cataracts, a common eye condition characterized by clouding of the lens, often lead to blurred vision and, if left untreated, ...

According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder affecting millions worldwide. The patent is supported by ...

The patent application, filed under Application Number N2039644, represents a significant step forward in the Company's intellectual property strategy. This milestone highlights Cosmos Health's ...